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Abstract
Introduction and Objective: The keratocystic odontogenic tumor is a benign but aggressive neoplasm. As enuclea-
tion alone obtains high recurrence rates, some adjuvant treatments such as Carnoy’s solution have been proposed. 
The aim of this study is to evaluate the reduction of recurrences with the use of Carnoy’s solution as adjuvant in 
the treatment of keratocystic odontogenic tumors. 
Material and Methods: An electronic search in Pubmed (MEDLINE), ScienceDirect and Cochrane databases was 
conducted with the key words “odontogenic keratocyst”, “keratocystic odontogenic tumor”, “carnoy’s solution”, 
“treatment” and “enucleation”. The inclusion criteria were clinical studies using Carnoy’s solution as adjuvant 
for the treatment of keratocystic odontogenic tumors, published in English, including at least 10 patients. Arti-
cles with an unclear reporting of the treatment applied, nonhuman studies, case reports and lesions associated to 
Gorlin-Goltz syndrome were excluded. 
Results: All the studies included were case series. The recurrence rate of enucleation ranged from 0% to 58.8%. 
With the only use of Carnoy’s solution as adjuvant treatment to the enucleation, recurrences varied from 0% to 
100%. The use of ≥ 2 adjuvant treatments reduced the range between 0% and 7.9%. 
Conclusions: The use of Carnoy’s solution as adjuvant therapy for the treatment of keratocystic odontogenic tumor 
has a grade C recommendation.
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Introduction
The odontogenic keratocyst was first described by 
Philipsen in 1956 (1). From the two histologic variants, 
the orthokeratinized one appears in 12% of cases and 
the parakeratinized variant of this entity in 90% of them 
(1,2). The later was renamed as keratocystic odontogenic 
tumor (KOT) by the World Health Organization (WHO) 
in 2005 that is a benign but aggressive neoplasm of od-
ontogenic origin, histologically characterized by a thin 
parakeratinized stratified squamous epithelium (1-9). 
Some cell proliferation markers as Ki-7, PCNA or p53 
have been found in the suprabasal zone (10). This tu-
mor can appear as a single or multiple lesions and even, 
as a part of nevoid basal cell carcinoma syndrome or 
Gorlin-Goltz syndrome (1,4,10). The higher incidence 
appears in patients ranging from 20 to 40 years old and 
its prevalence is higher in men than in women, in a 2:1 
proportion (9,11).
The histopathological analysis is necessary to estab-
lish the definitive diagnosis. An incisional or excisional 
biopsy, or a fine-needle aspiration biopsy are the most 
used techniques to obtain a sample (2), although the 
presence of inflammatory infiltrate can impair the diag-
nosis and give rise to false negatives (1,2).
Radiologically, it appears as a unilocular or multilocu-
lar well-defined lesion with scalloped margins (10). It 
can be associated with an included tooth. The differen-
tial diagnosis includes the dentigerous or follicular cyst, 
radicular cyst, periodontal lateral cyst and ameloblas-
toma, among others (2,9,12). The most frequent location 
is in mandible (70-75%), particularly in the angle and 
mandibular ramus (1,5,9-11,13).
High recurrence rates have been described for this le-
sion (4,5,9,12,14) mainly depending on the treatment 
modality as it will determine a complete or incomplete 
cyst removal (3,7). In addition, a new primary cyst for-
mation in the proximity of the former could be inter-
preted as a recurrence (8).
Enucleation is the treatment of choice although it can 
result in a 60% of recurrences (9). Thus, other adjuvant 
treatments such as cryotherapy, peripheral ostectomy 
with rotary instruments, excision of the adhered muco-
sa, electrocoagulation, Carnoy’s solution, marsupializa-
tion, decompression and secondary excision or resec-
tion have been used (4,6-8,12). 
Carnoy’s solution (CS) is a cauterizing agent that causes 
a rapid local fixation. The solution can be used inside the 
cyst to facilitate a complete remotion of the cystic mem-
brane or directly over the bony bed after the cyst enucle-
ation to detect and eliminate the remaining epithelium of 
the KOT to diminish the likelihood of a recurrence (5). 
The aim of this systematic review was to evaluate the 
reduction of recurrences associated to the application of 
Carnoy’s solution as adjuvant in the treatment of kera-
tocystic odontogenic tumors.
Material and Methods
This article follows the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) 
declaration (15). The selected articles were classified in 
different levels of evidence by means of the Strength of 
Recommendation Taxonomy (SORT) criteria (16). 
An electronic search in Pubmed (MEDLINE), Science-
Direct and Cochrane databases. The last search was 
conducted on 27th February 2015. The keywords used 
were “odontogenic keratocyst”, “keratocystic odon-
togenic tumor”, “carnoy’s solution”, “treatment” and 
“enucleation”. The Boolean operator “AND” was used 
in order to obtain the most relevant studies. 
The inclusion criteria were prospective or retrospective 
clinical studies using CS as adjuvant treatment for the 
treatment of primary KOT, articles published in English, 
including at least 10 patients with a diagnosed KOT. The 
exclusion criteria were studies with unclear reporting of 
the treatment applied, nonhuman studies, case reports 
and lesions associated to Gorlin-Goltz syndrome. 
The articles selection was agreed by consensus between 
two of the authors; first by reading of titles and abstracts 
of the found bibliographic cites to identify the most rele-
vant studies and then, by means of reading the full-text. 
No metaanalysis could be done due to the heterogeneity 
of the studies included. 
Results
The flow chart of the selected articles can be seen in 
figure 1. Among the 644 studies initially obtained from 
the search, 605 were excluded by reading the title and 
abstract. Thus, the complete text of 39 articles was ana-
lyzed by the two authors. Sixteen articles (17-32) were 
excluded; the reasons are detailed in table 1. Thus, 
twenty-three articles with relevance were selected to be 
included in the systematic review: 5 systematic reviews 
(6,7,9,33,34), 4 reviews (1,2,10,11), 10 retrospective 
(3-5,8,14,35-40) and 3 prospective studies (12,13,41). 
Concretely, 13 articles were subjected to data extraction 
and complete analysis. Despite all these studies had a 
scientific level 3 and no randomized clinical trials could 
be found, the authors decided to include them to analyze 
the available literature. The main results of the included 
clinical studies are shown in table 2. It should be noted 
that the studies performed by Zhao et al. (14) and Rao 
and Kumar (37) did not clearly specify the presence of 
the parakeratotic component.
The recurrence rates for enucleation varied from 0 to 
58.8% in a period of time ranging from 3 months to 
16 years. The use of Carnoy’s solution as adjuvant to 
enucleation had recurrence rates from 0 to 100% in a 
time period of 3 months to 9 years. Interestingly, the 
use of two or more adjuvant techniques had a 0 to 7.9% 
of recurrences between 1 and 16 years. Even though, 
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the treatments that included two or more adjuvant tech-
niques were performed in less patients than the others.
Discussion
As previously explained, KOT is a benign but aggressive 
neoplasm of odontogenic origin (3-9). High recurrence 
rates have been described for this lesion (4,5,9,12,14,37) 
mainly depending on the treatment modality (3,7). Ac-
cordingly, a recently published study (40) quantified 
Cyclin D1 (CCD1) expression levels, a nuclear protein 
essential for cell cycle progression, in a series of kera-
tin-producing odontogenic cysts. They concluded that 
these levels did not predict non syndromic KOT recur-
rences and that factors not related to the lesion biology 
could have an influence in the recurrence rates.
Regarding to radiological appearance, lesions with scal-
loped and often corticated margins or a multilobular and 
multilocular appearance can be observed (4, 9,12,14,35). 
Displacement of impacted or erupted teeth, root resorp-
tion, root displacement or extrusion of erupted teeth 
can occur (4). These lesions are difficult to interpret and 
easy to be confused with other lesions (12,14). Often as-
ymptomatic, the majority of KOT tends to appear at the 
mandible, frequently at the mandibular ramus and angle 
(3,4,9,14,37), although it can also occur in the dentate 
area of the jaws resembling an odontogenic cyst (12). 
Even, involvement with an impacted tooth has been de-
scribed up to 40% of cases (4,35).
The different treatment modalities can be divided in 
conservative methods such as enucleation, decompres-
sion or marsupialization and in invasive ones, that is, 
cryosurgery or resection (6,36). Although the most radi-
!Fig. 1. Flow of articles through the systematic review according to the PRISMA statement.
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cal treatments have shown the lower recurrence rates, 
available evidence does not demonstrate the most ef-
fective technique in terms of morbidity and recurrence 
prevention (3,5,6,8,38). 
Enucleation is the most commonly used method to treat 
the majority of KOT, although with a high rate of recur-
rences (9).  Thus, adjuvant techniques such as the use of 
CS either before the cyst enucleation or placed directly 
in the bony bed after the enucleation have been proposed 
to eliminate residual tissue and so prevent recurrences 
(3,5,7,9,14). Although CS was initially described to be 
placed into the cyst lumen before enucleation, most 
clinicians apply it after (7,33). This aspect could intro-
duce a bias at the time of analyzing the recurrence rates. 
CS is a cauterizing and fixating agent that penetrates 
cancellous spaces in the bone (3,6,36). The time of ap-
plication is sufficient for 10 to 15 minutes, although if 
inferior alveolar nerve is visible into the cyst cavity, the 
application cannot last for more than 3 minutes because 
of damage of nerve fibers has been described (14).
Some authors defend that techniques such as marsupi-
alization with posterior enucleation are better for larger 
cysts to reduce the morbidity and to be more conserva-
tive (7,9,14). Others state that more invasive techniques 
such as resection have to be reserved for recurrent KOT 
with the aim to eliminate satellite cysts or epithelial 
remnants (3,7,14).
The different adjuvant techniques used in the studies 
included in this systematic review for the treatment of 
KOT difficult the analysis of the application of CS as a 
unique adjuvant treatment apart from the enucleation. 
CS has been used in combination with enucleation, pe-
ripheral ostectomy, curettage, marsupialization and ex-
cision of affected mucosa. As found in this study, not 
only the use of CS but also the use of multiple adjuvant 
treatments reduce the recurrence rates compared to 
enucleation alone. 
Regarding to the limitations of the included studies, the 
differences in the number of participants around the 
distinct treatments performed difficult to draw conclu-
sions. In a study made by Chow (36), one patient was 
treated by means of enucleation, CS, peripheral ostec-
tomy and cryotherapy. Although the lesion did not re-
curred it is not possible to state that the combination 
of this techniques yields the best results, similarly to 
other treatments performed in some of the included 
studies (5,8,12,35).  The studies published by Stoelinga 
(12), Zhao et al.. (14) (both published prior to 2005) and 
Güler et al. (4) and Rao and Kumar (37) did not specify 
the histologic variant of the treated odontogenic kerato-
cysts. Thus, a risk of bias in the results could have been 
introduced. In the retrospective study of Ribeiro et al. 
(5), they did not specify in which cases the excision of 
mucosa was done.  With regard to the cases that had 
been followed up, the study from Guler et al. (4) only 
revisited a 32.5% of patients and Rao and Kumar (37) 
did only control visits in 12 from 32 cases. 
The retrospective nature of some of the included studies 
has several limitations such as different lengths of fol-
low-up. The study of Gosau et al. (3) found that lesions 
treated by means of enucleation plus CS had a recur-
rence rate of 14.3% whereas the cases treated with enu-
AUTHOR EXCLUSION CRITERIA
Dammer et al. (17) 1997 Unclear reporting of distribution of the different treatments performed
Ghali et al. (18) 2003 Literature review that does not discuss the use of Carnoy’s solution
Pitak-Arnnop et al. (19) 2010 This study does not include the use of Carnoy’s solution
Boffano et al. (20) 2010 This study does not include the use of Carnoy’s solution
Finklestein et al. (21) 2013 This study does not include the use of Carnoy’s solution
Sivanmalai et al. (22) 2012 Case report
Kolokythas et al. (23) 2007 This study does not include the use of Carnoy’s solution
Zecha et al. (24) 2010 This study does not include the use of Carnoy’s solution
Zhao et al. (25) 2012 All the treated cases are recurrences of a primary KOT
Pitak-Arnnop et al. (26) 2010 Letter to the Editor
Rajeshkumar et al. (27) 2013 Study with only 7 patients diagnosed of KOT 
Yang et al. (28) 2011 This study does not include the use of Carnoy’s solution
Kinard et al. (29) 2013 Unclear reporting of distribution of the different treatments performed
Myoung et al. (30) 2001 This study does not include the use of Carnoy’s solution
Tolstunov and Treasure (31) 2008 Case report
Chapelle et al. (32) 2004 The study involves the treatment of ameloblastomas
Table 1. List of excluded studies and reasons.
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Author Type of study Treatment Lesions Recurrences (%) 
Recurrence interval 
(average) 
Follow-up  
(average) 
Gosau et al. (3) 2010  
 
Retrospective 
E 22 11 (50%) 
7 mo – 68 mo  
(35.6 mo) 
12 mo – 120 mo  
(67.4 mo) 
E + CS 14 2 (14.3%) 1 y – 29 mo (18.5 mo) 
12 mo – 120 mo  
(45.6 mo) 
Güler et al. (4) 2012  
 
Retrospective 
E 18 0 - 
20 y – 29 y E + CS 10 0 - 
E + M + CS 15 0 - 
Ribeiro-Junior et al.  
(5) 2012  
 
Retrospective 
E + PO + CS 9 0 - 18 mo – 78 mo  
(42.9 mo) M + E + CS + PO 2 0 - 
Morgan et al.  
(8) 2005  
Retrospective 
E 11 6 (54.5%) 
3 mo – 106 mo  
(49.1 mo) 
13 mo – 288 mo  
(63.7 mo) 
E + CS 2 1 (50%) 
3 mo – 106 mo 
 (49.1 mo) 
E + PO 11 2 (18.2%) 
      3 mo – 106 mo  
          (49.1 mo) 
E + PO + CS 13 0 - 
R 3 0 - 
Stoelinga (12) 2001  Prospective 
E 33 6 (18.2%) 1 y – 16 y 
2 y – 25 y  (11.8 y) 
E + EAM 6 0 - 
E + CS 5 0 - 
E + EAM + CS 38 3 (7.9%) 1 y - 16 y 
Titinchi & Nortje 
(13) 2012  
Prospective 
E 50 15 (30%) 13 mo 
(19.8 mo) 
M 5 3 (60%) 23.5 mo 
E + CS 9 1 (11.1%) 12.6 mo 
R 1 0 - 
Zhao et al. (14) 2002  Retrospective 
E 163 29 (17.8%) 2 y - 13 y 
3 y – 29 y  (7.8 y) 
E + CS 29 2 (6.7%) 2 y - 13 y 
E + M 11 0 - 
R 52 0 - 
Chirapathomsakul  
et al. (35) 2006  
Retrospective 
M 6 1 (16.7%) 2 y - 10 y 
1 y – 14.6 y 
E 15 2 (13.3%) 12 mo - 56 mo 
E + CS 5 1 (20%) 2 y - 10 y 
E + CU 2 2 (100%) 2 y - 10 y 
R 7 1 (14.2%) 18 mo-68 mo 
Chow (36) 1998  Retrospective 
E + PO 52 5 (9.6%) 2 y - 10 y 
Not cited E + PO + CS 23 1 (4.3%) 2 y 
E + PO + CS+CR 1 0 - 
Rao & Kumar  
(37) 2012  
Retrospective E + CS 32 2 (6.3%) 2.8 y 7 y – 17 y (2.8 y) 
Sánchez-Burgos et al.  
(38) 2014  
Retrospective 
E + PO 49 11 (22.4%) 8 mo – 9 y (5 y) 
8 mo – 9 y (5 y) 
E + CS 2 2 (100%) 8 mo – 9 y (5 y) 
M 2 1 (50%) 8 mo – 9 y (5 y) 
R 2 0 - 
Schussel et al.  
(39) 2011  
Retrospective 
E 17 10 (58.8%) 9 mo – 41 mo 
         1 y – 7 y   (3 y) E + CS 1 0 - 
E + CR 4 2 (50%) 17 mo – 30 mo 
Apajalahti et al.  
(41) 2011  
Prospective E + CS 46 19 (39%) 0.6 y – 3.4 y (2.2 y) 1 y – >8 y (4.7 y) 
Table 2. Characteristics of the clinical studies included in this systematic review regarding to the type of study, the treatments performed, 
the recurrences and the time of recurrence.
The treatments that include the use of Carnoy’s solution appear highlighted in grey. E: enucleation, EAM: excision of adhered mucosa, CS: 
Carnoy’s solution, CU: curettage, CR: cryotherapy, M: marsupialization, PO: peripheral ostectomy, R: resection, mo: months, ys: years.
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cleation had a 50% of recurrences. However, the length 
of follow-up was shorter in the first group (18.5 months 
as average) than in the enucleation group (36.5 months). 
Most studies recommend the need of a long-term fol-
low-up at regular intervals after surgery (7,8,35,38,39). 
A follow-up of 5 years or more is recommended because 
some recurrences have been reported 16 years after the 
initial treatment (12). Morgan et al. (8) studied the pos-
sibility of having more recurrences because of a longer 
follow-up and they did not found significant differences 
between the mean time to recurrence for patients with 
recurrence and the mean follow-up for patients without 
recurrence. As stated by Antonoglou et al. (34), the dif-
ferent times of follow-up among the studies and the lack 
of histopathologic data in some of them could introduce 
a bias in the results. Moreover, there are no randomized 
clinical trials performed for the treatment of KOT, as 
stated by the Sharif and Oliver systematic review (9). 
Future research with randomized and/or controlled 
clinical studies, with similar samples or number of le-
sions treated and with a long-term follow-up is needed 
to obtain consistent results.
Conclusions
The lack of randomized clinical trials, the methodologi-
cal differences and the low level of evidence of the in-
cluded studies allow to conclude that the use of Car-
noy’s solution as adjuvant therapy for the treatment of 
KOT has a grade C recommendation and that there is 
not a clear reduction in the recurrences.
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